Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients.
Glucocorticoid (GC)-induced osteoporosis contributes to chronic damage in patients suffering from connective tissue diseases (CTD) such as systemic lupus erythematosus (SLE). In this study, performed in an highly selected cohort of premenopausal female CTD (mostly lupus) patients, given high-dose GC therapy for severe disease, we show that lumbar spine bone loss can be averted by treatment with oral disodium pamidronate combined with calcium salts and vitamin D3 supplements and not by calcium salts and vitamin D3 supplements alone. We stress the need for optimal GC-induced bone loss prevention therapy in premenopausal patients, a too often neglected issue in patients whose survival has dramatically improved over the last decades.
Nzeusseu Toukap
A
A
Rheumatology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium.
Depresseux
G
G
Devogelaer
J-P
JP
Houssiau
F A
FA
D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015519:Bone Density; D016723:Bone Remodeling; D003240:Connective Tissue Diseases / Q000188:drug therapy; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008159:Lumbar Vertebrae; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D000077268:Pamidronate; D010384:Pelvic Bones; D017697:Premenopause; D011446:Prospective Studies
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D000077268:Pamidronate